Zai Lab (ZLAB) Set to Announce Earnings on Tuesday

Zai Lab (NASDAQ:ZLAB) is scheduled to issue its quarterly earnings data before the market opens on Tuesday, November 12th. Analysts expect the company to announce earnings of ($0.71) per share for the quarter. Investors that are interested in registering for the company’s conference call can do so using this link.

Zai Lab (NASDAQ:ZLAB) last announced its quarterly earnings data on Tuesday, August 6th. The company reported ($0.82) EPS for the quarter, missing the consensus estimate of ($0.66) by ($0.16). The company had revenue of $100.50 million during the quarter, compared to the consensus estimate of $94.46 million. Zai Lab had a negative return on equity of 37.96% and a negative net margin of 92.44%. On average, analysts expect Zai Lab to post $-3 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Zai Lab Price Performance

Zai Lab stock opened at $30.89 on Tuesday. The firm has a 50 day moving average price of $24.26 and a 200-day moving average price of $20.24. Zai Lab has a twelve month low of $13.48 and a twelve month high of $36.60.

Analysts Set New Price Targets

ZLAB has been the subject of a number of recent research reports. Cantor Fitzgerald reissued an “overweight” rating on shares of Zai Lab in a research report on Friday, October 25th. JPMorgan Chase & Co. raised their price target on Zai Lab from $38.00 to $44.00 and gave the stock an “overweight” rating in a report on Monday, October 21st.

Insider Buying and Selling

In other Zai Lab news, insider Joshua L. Smiley sold 4,352 shares of the stock in a transaction that occurred on Friday, August 16th. The shares were sold at an average price of $16.67, for a total value of $72,547.84. Following the sale, the insider now directly owns 43,232 shares in the company, valued at $720,677.44. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 13.88% of the stock is currently owned by insiders.

Zai Lab Company Profile

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis.